New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
08:55 EDTCLDXCelldex price target raised to $15 from $9 at Jefferies
Jefferies increased its price target on Celldex as the firm believes that the company's pipeline outlook was encouraging. The firm views Celldex as a compelling biotech play with multiple shots on goal and it maintains a Buy rating.
News For CLDX From The Last 14 Days
Check below for free stories on CLDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:19 EDTCLDXLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 7, 2014
16:02 EDTCLDXCelldex says CDX-014 to enter clinical development
Celldex Therapeutics reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate that targets the protein TIM-1. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015," said Tibor Keler, senior VP and Chief Scientific Officer of Celldex.
April 4, 2014
09:50 EDTCLDXCelldex management to meet with Guggenheim
Meetings to be held in New York on April 10-11 hosted by Guggenheim.
April 3, 2014
08:27 EDTCLDXLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
08:11 EDTCLDXCelldex to present CDX-014 preclinical proof of concept data at AACR
Celldex Therapeutics announced that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate CDX-014 will be presented at the American Association of Cancer Research, or AACR, Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1, which is upregulated in several cancers, including renal and ovarian carcinomas.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use